Latest Articles about RPRX

Repros to Conduct Phase IIb Trial - Analyst Blog

Zacks Equity Research — Fri, 24 May 2013 02:30:20 Z

Recently, the US Food and Drug Administration (FDA) recommended Repros Therapeutics Inc. ( RPRX ) to conduct a phase IIb trial on its pipeline candidate, Proellex-V before commencing phase

Investor sticks with winner in Repros

David Russell — Wed, 01 May 2013 12:46:42 Z

Repros Therapeutics has rallied hard, and one investor is adjusting a winning trade. optionMONSTER's Heat Seeker monitoring program detected the sale of 1,850 November 17.50 calls for $5.92 in

Repros Gets Additional Patents - Analyst Blog

Zacks Equity Research — Sat, 13 Apr 2013 01:09:02 Z

Repros Therapeutics Inc. ( RPRX ) recently announced that two additional patents covering its candidate, Androxal, have been issued. Both patents (8,372,887 and 8,377,991) related to

Positive Data on Repros' Androxal - Analyst Blog

Zacks Equity Research — Fri, 05 Apr 2013 01:09:21 Z

Repros Therapeutics Inc. ( RPRX ) recently provided top-line results from the ZA-301 study on its late-stage candidate, Androxal, which is being evaluated for the treatment of secondary

Repros Delays ZA-301 Study Results - Analyst Blog

Zacks Equity Research — Fri, 01 Feb 2013 02:50:01 Z

Repros Therapeutics Inc. ( RPRX ) recently announced that results from the first pivotal study (ZA-301) of Androxal will be declared in the third quarter of 2013 instead of the second

Repros Provides Androxal Update - Analyst Blog

Zacks Equity Research — Tue, 15 Jan 2013 03:15:01 Z

Repros Therapeutics Inc. ( RPRX ) recently provided an update on its phase III program for Androxal. The candidate is being evaluated for the treatment of secondary hypogonadism. The

Update on Repros' Androxal - Analyst Blog

Zacks Equity Research — Sat, 15 Sep 2012 01:34:14 Z

Repros Therapeutics Inc. ( RPRX ) recently provided an update on its phase III program, Androxal indicated for the treatment of secondary hypogonadism. The company has started randomizing

Earnings Miss at Repros - Analyst Blog

Zacks Equity Research — Fri, 17 Aug 2012 22:57:01 Z

Repros Therapeutics Inc. ( RPRX ) recently reported second quarter 2012 loss of 21 cents per share, wider than the Zacks Consensus Estimate of a loss of 17 cents but narrower than the

Repros Therapeutics Inc. Enters Oversold Territory - Tale of the Tape

Zacks Equity Research — Mon, 16 Jul 2012 19:17:01 Z

Repros Therapeutics Inc. 's ( RPRX ) share price has entered into oversold territory with a stochastic value of 18.6275. The Zacks Consensus Estimate on the company's loss for year ending

The Strongest Small-Caps in the Market

Benzinga — Tue, 22 May 2012 00:04:30 Z

Traders who are comfortable with a high level of risk/reward frequently will gravitate to the small-cap space where big gains (and losses) in a short amount of time are commonplace. One

Options Market Picks: 9 Highly Liquid Stocks with Bullish Options Sentiment

Kapitall — Thu, 17 Nov 2011 05:55:13 Z

( Written by Rebecca Lipman. List compiled by Eben Esterhuizen, CFA. Options data sourced from Schaeffer’s. Accounting data sourced from Google Finance. ) Stock options are interesting because